Form 4: Blueprint Medicines Director Goldberg Receives Stock and Option Grants

Director Mark Alan Goldberg received restricted stock units and stock options from Blueprint Medicines Corp on June 12, 2024.

Summary

• On June 12, 2024, Mark Alan Goldberg, a director of Blueprint Medicines Corp, received a grant of 2,242 restricted stock units and an option to purchase 4,570 shares of common stock.
• The restricted stock units vest on the earlier of June 12, 2025, or the date of the next annual meeting of the Issuer's stockholders.
• Each restricted stock unit represents a contingent right to receive one share of Blueprint Medicines' common stock.
• The stock option has an exercise price of $106.14 and also vests on the earlier of June 12, 2025, or the date of the next annual meeting of the Issuer's stockholders, and expires on June 12, 2034.
• Following these transactions, Goldberg beneficially owns 18,254 shares of common stock and options to purchase 4,570 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company's success.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon continued service until the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders.

Industry Context

Stock grants and options are common forms of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies like Vertex Pharmaceuticals or Amgen also utilize stock options and restricted stock units as part of their director compensation packages.

Stakeholder Impact

• The stock and option grants incentivize the director to act in the best interests of the shareholders.
• The grants have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates